These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 20858196)

  • 1. Drug screening for Huntington's disease and other neurodegenerative disorders.
    Varma H
    Curr Mol Pharmacol; 2010 Nov; 3(3):164-73. PubMed ID: 20858196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High throughput screening for neurodegeneration and complex disease phenotypes.
    Varma H; Lo DC; Stockwell BR
    Comb Chem High Throughput Screen; 2008 Mar; 11(3):238-48. PubMed ID: 18336216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small molecule drug discovery for Huntington's Disease.
    Fecke W; Gianfriddo M; Gaviraghi G; Terstappen GC; Heitz F
    Drug Discov Today; 2009 May; 14(9-10):453-64. PubMed ID: 19429504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expanding therapeutic opportunities for neurodegenerative diseases: A perspective on the important role of phenotypic screening.
    Swalley SE
    Bioorg Med Chem; 2020 Feb; 28(3):115239. PubMed ID: 31889605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Xyloketal-derived small molecules show protective effect by decreasing mutant Huntingtin protein aggregates in Caenorhabditis elegans model of Huntington's disease.
    Zeng Y; Guo W; Xu G; Wang Q; Feng L; Long S; Liang F; Huang Y; Lu X; Li S; Zhou J; Burgunder JM; Pang J; Pei Z
    Drug Des Devel Ther; 2016; 10():1443-51. PubMed ID: 27110099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small Molecules: Therapeutic Application in Neuropsychiatric and Neurodegenerative Disorders.
    Schiavone S; Trabace L
    Molecules; 2018 Feb; 23(2):. PubMed ID: 29438357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemical screening platforms for autophagy drug discovery to identify therapeutic candidates for Huntington's disease and other neurodegenerative disorders.
    Sarkar S
    Drug Discov Today Technol; 2013; 10(1):e137-44. PubMed ID: 24050242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotypic screens targeting neurodegenerative diseases.
    Zhang M; Luo G; Zhou Y; Wang S; Zhong Z
    J Biomol Screen; 2014 Jan; 19(1):1-16. PubMed ID: 23958650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic approaches to preventing cell death in Huntington disease.
    Kaplan A; Stockwell BR
    Prog Neurobiol; 2012 Dec; 99(3):262-80. PubMed ID: 22967354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From target identification to drug screening assays for neurodegenerative diseases.
    Zuccato C; Tartari M; Goffredo D; Cattaneo E; Rigamonti D
    Pharmacol Res; 2005 Sep; 52(3):245-51. PubMed ID: 15916902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deep-learning analysis of micropattern-based organoids enables high-throughput drug screening of Huntington's disease models.
    Metzger JJ; Pereda C; Adhikari A; Haremaki T; Galgoczi S; Siggia ED; Brivanlou AH; Etoc F
    Cell Rep Methods; 2022 Sep; 2(9):100297. PubMed ID: 36160045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone post-translational modifications in Huntington's and Parkinson's diseases.
    Peña-Altamira LE; Polazzi E; Monti B
    Curr Pharm Des; 2013; 19(28):5085-92. PubMed ID: 23448464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical potential of minocycline for neurodegenerative disorders.
    Blum D; Chtarto A; Tenenbaum L; Brotchi J; Levivier M
    Neurobiol Dis; 2004 Dec; 17(3):359-66. PubMed ID: 15571972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Caenorhabditis elegans as a model system for target identification and drug screening against neurodegenerative diseases.
    Ma L; Zhao Y; Chen Y; Cheng B; Peng A; Huang K
    Eur J Pharmacol; 2018 Jan; 819():169-180. PubMed ID: 29208474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain oxidative stress in animal models of accelerated aging and the age-related neurodegenerative disorders, Alzheimer's disease and Huntington's disease.
    Butterfield DA; Howard BJ; LaFontaine MA
    Curr Med Chem; 2001 Jun; 8(7):815-28. PubMed ID: 11375752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system.
    Aymerich MS; Aso E; Abellanas MA; Tolon RM; Ramos JA; Ferrer I; Romero J; Fernández-Ruiz J
    Biochem Pharmacol; 2018 Nov; 157():67-84. PubMed ID: 30121249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experimental therapeutics of neurodegenerative disorders: unmet needs.
    Shoulson I
    Science; 1998 Nov; 282(5391):1072-4. PubMed ID: 9804537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroprotection of Coenzyme Q10 in Neurodegenerative Diseases.
    Yang X; Zhang Y; Xu H; Luo X; Yu J; Liu J; Chang RC
    Curr Top Med Chem; 2016; 16(8):858-66. PubMed ID: 26311425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of Small Molecules that Induce the Degradation of Huntingtin.
    Tomoshige S; Nomura S; Ohgane K; Hashimoto Y; Ishikawa M
    Angew Chem Int Ed Engl; 2017 Sep; 56(38):11530-11533. PubMed ID: 28703441
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.